Denis Lacombe, M.D., has been appointed Director General of the Brussels-based European Organisation for Research and Treatment of Cancer (EORTC).
Denis Lacombe, M.D., has been appointed Director General of the Brussels-based European Organisation for Research and Treatment of Cancer (EORTC).
“The cancer clinical research environment has become increasingly complex over the years, but I am confident that together with my upper management team at EORTC Headquarters, Vassilis Golfinopoulos, Medical Director, Jan Bogaerts, Methodology Director, and Christian Brunet, Chief Financial Officer, the EORTC can adapt and thrive in this rapidly changing environment,” he noted in a statement issued on 3 April. “I have known many of you for years, and I look forward to continuing and strengthening our working relationships.”
Lacombe took a post-doctoral fellowship in Fundamental and Clinical Pharmacokinetics at the Roswell Park Cancer Institute, Buffalo, NY, between 1989 and 1991. He then worked as Clinical Research Adviser in charge of the development of a new oncology drug in the pharmaceutical industry, and was involved in the management of the phase I and phase II studies in Europe.
He joined EORTC in September 1993 as Clinical Research Physician. Between 1993 and 2006, he was in charge of the Regulatory Affairs Unit, and was a regular speaker at the Applied Clinical Trials European Summit. Between 2003 and 2009, Lacombe was a Clinical Research Physician for the Head & Neck Tumor Group, and is still a Clinical Research Physician for the Brain Tumor and the Lung Groups. Until 2007, as Assistant Director of Medical Affairs, he coordinated the EORTC New Drug Development Team (NDD Team), which supported EORTC clinical groups conducting new drug development studies from protocol development to publication. In November 2007, he became Scientific Director of the EORTC.
The longstanding director general, Françoise Meunier, has moved to a new role within the operation. She became Director of Special Projects on 1 April, and will represent the organization externally, coordinate fundraising activities, and sit on the board of EORTC Cancer Research Fund.
The EORTC is an independent research organization dedicated to investigator driven clinical trials and translational research. Consisting of both a network and a coordinating scientific and operational infrastructure, it seeks to not only establish ‘state-of-the-art’ treatments but also ensure that new cancer agents are developed and tested efficiently with the aim of minimizing delays between laboratory discovery and their therapeutic benefit for patients.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.